![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600.jpg?resize=150%2C150&ssl=1 "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? 15")
| Audience | Pediatric neurologists, epileptologists, family physicians, and cannabis medicine clinicians managing Dravet syndrome patients on CBD-based or multidrug antiseizure regimens |
| Primary Topic | A post hoc pooled analysis of three phase 3 randomized controlled trials examining fenfluramine efficacy and safety in Dravet syndrome, stratified by age, prior antiseizure medication exposure, and SCN1A genotype, published in Epilepsia Open, August 2026 |
| Source | Read the study on PubMed |
A pooled post hoc analysis of three phase 3 randomized trials in 348 children and adolescents with Dravet syndrome found that fenfluramine reduced convulsive seizures and improved global functioning across nearly every age, prior-treatment, and SCN1A genotype subgroup, with no cases of valvular heart disease or pulmonary hypertension reported and a consistent safety profile throughout.
| Study Type | Post hoc pooled analysis of patient-level data from three phase 3, randomized, double-blind, placebo-controlled trials |
| Population | 348 patients with Dravet syndrome aged 2-18 years (fenfluramine n=216; placebo n=132) pooled across three RCTs |
| Stratification | Age (<4 vs >=4 years), number of previously attempted ASMs (1-3, 4-6, >=7), and SCN1A pathogenic variant status (positive vs negative) |
| Intervention | Fenfluramine 0.7 mg/kg/day (n=88) or 0.2 mg/kg/day (n=85) without stiripentol, or 0.4 mg/kg/day (n=43) with stiripentol, versus placebo |
| Primary Efficacy Measure | Median percentage change in monthly convulsive seizure frequency (MCSF) versus pretreatment baseline |
| MCSF Finding by Age | Age >=4 years: -57.1% vs placebo (p<0.0001); age <4 years: -42.1% (p=0.0562, not significant) |
| MCSF Finding by Genotype | SCN1A+: -53.8% (p<0.0001); SCN1A-: -63.5% (p<0.0001) |
| Seizure-Free Interval | Significantly longer than placebo in patients >=4 years (+10 days, p<0.0001) and across all prior-ASM strata (+6.0 to +12.5 days); not significant in patients <4 years (+2.5 days) |
| CGI-I Response | Significantly higher rates of clinically meaningful improvement (Much/Very Much Improved) across all strata except the <4 years subgroup |
| Safety | Any treatment-emergent adverse event: 94.0% fenfluramine vs 81.8% placebo; no valvular heart disease or pulmonary arterial hypertension in any group; 2.9% (10/348) discontinued due to a TEAE |
| Journal | Epilepsia Open |
| Published | August 22, 2026 |
| DOI | 10.1002/epi4.70340 |
| PMID | 42632015 |
| Funding | UCB (manufacturer of fenfluramine/Fintepla); most authors report research funding, consulting fees, or employment ties to UCB |
Researchers pooled individual patient data from three pivotal phase 3, double-blind, placebo-controlled trials of fenfluramine in Dravet syndrome, comprising 348 patients aged 2 to 18 years across three dose regimens (0.7 mg/kg/day and 0.2 mg/kg/day without stiripentol; 0.4 mg/kg/day with stiripentol) versus placebo.
The pooled group was then stratified post hoc by age at trial entry, number of antiseizure medications previously attempted before enrollment, and SCN1A pathogenic variant status, allowing the authors to ask whether fenfluramine’s benefit held up consistently across these clinically important subgroups rather than being driven by one favorable population.
In patients 4 years or older, fenfluramine reduced monthly convulsive seizure frequency by a median of 57.1% relative to placebo (p<0.0001), and the benefit was significant across all three prior-ASM strata (1-3 ASMs: -46.5%, p=0.0006; 4-6 ASMs: -58.8%, p<0.0001; 7 or more ASMs: -55.7%, p=0.0002) and both SCN1A-positive (-53.8%, p<0.0001) and SCN1A-negative (-63.5%, p<0.0001) genotypes.
Seizure-free intervals lengthened significantly in the same subgroups, and clinically meaningful global improvement on the CGI-I scale, as rated by both parents/caregivers and investigators, was significantly more common with fenfluramine than placebo in every stratum except children younger than 4 years.
Among the 44 patients younger than 4 years, the smallest and least-represented subgroup, MCSF reduction trended favorably (-42.1%) but did not reach statistical significance (p=0.0562), the seizure-free interval difference was small (+2.5 days) and not significant, and a smaller proportion of this age group showed clinically meaningful CGI-I improvement compared with older children.
The authors attribute this partly to the group’s small sample size rather than a true absence of effect, and note that a higher proportion of placebo-treated children under 4 showed improvement than older placebo-treated children, which complicates interpretation of this specific subgroup.
This trial did not test cannabidiol, THC, or any cannabis-derived product in any form, and none of its findings should be read as evidence about cannabinoid efficacy or safety in Dravet syndrome. Its relevance to cannabis medicine is entirely about the patient population and treatment landscape, not the intervention studied.
Cannabidiol, marketed as Epidiolex, is the only cannabis-derived medicine with FDA approval for Dravet syndrome, and clinicians managing these patients frequently combine it with other antiseizure medications. As fenfluramine becomes an increasingly common addition to that regimen, subgroup data like this can help clinicians and families understand which patients are most likely to benefit from adding it alongside CBD-based therapy, without implying any interaction or comparison was actually tested here.
At least one treatment-emergent adverse event occurred in 94.0% of the pooled fenfluramine group versus 81.8% of placebo, with decreased appetite, diarrhea, and pyrexia the most common. These typically began sooner with fenfluramine (24.1 to 30.1 days on average) than placebo (41.0 days) and resolved by end of treatment in 82.6% of fenfluramine-treated patients versus 72.7% of placebo-treated patients.
No cases of valvular heart disease or pulmonary arterial hypertension, the historical safety concerns associated with fenfluramine when it was previously used as a weight-loss drug at much higher doses, were reported in any of the three RCTs. The authors note that infrequent post-marketing cases of these conditions have nonetheless been reported in Dravet and Lennox-Gastaut patients treated with fenfluramine within the approved dose range, often involving confounding factors, which supports continued echocardiographic monitoring in clinical practice.
Dravet syndrome treatment has expanded substantially over the past decade, from a landscape dominated by valproate, clobazam, and stiripentol to one that now includes cannabidiol (Epidiolex, FDA-approved in 2018 as the first plant-derived cannabinoid medicine for this indication) and fenfluramine (Fintepla, approved shortly after), each targeting seizures through entirely different pharmacologic mechanisms.
This pooled analysis reflects a broader trend in Dravet syndrome research: as more add-on therapies become available, researchers and clinicians increasingly need subgroup-level data to guide which patients are most likely to benefit from which combination, rather than treating every antiseizure medication as interchangeable across the full patient population.
I see Dravet syndrome patients whose seizure-control plans already include CBD, and what strikes me about this analysis is how directly it speaks to the multidrug reality of managing this disease. Fenfluramine reduced seizures and improved global functioning in the vast majority of patients regardless of age, prior treatment history, or genotype, and that kind of consistency is genuinely useful when I am thinking through where fenfluramine might fit for a family already on a CBD-based regimen.
I also want to be direct about what this study is not. It is not a cannabis trial, and nothing here tells me how fenfluramine interacts with CBD, or whether combining them changes outcomes in either direction. UCB funded this study and most of the authors have financial ties to the company, which is common in industry-sponsored antiseizure medication research but still worth naming plainly. What I take from this is useful subgroup context for a drug many of my patients are already using or considering, not new evidence about cannabinoid medicine itself.
How to Read a Post Hoc Subgroup Analysis of an Industry-Funded Trial
This analysis’s headline result, that fenfluramine works consistently across most Dravet syndrome patient subgroups, is genuinely well supported by the pooled sample size. Its subgroup-specific claims rest on statistically thinner, unadjusted ground.
Four checks keep this analysis’s real contribution from being overstated in either direction, toward cannabinoid relevance it does not have, or away from the subgroup consistency it does show.
A Four-Step Reading Frame
Separate the original trials from this post hoc analysis
The three RCTs were powered for their own primary endpoints; this stratified breakdown was not prespecified, and every p-value here is labeled nominal.
Note what was never tested
Cannabidiol, THC, and cannabis-derived products do not appear anywhere in this study. Its relevance to cannabis medicine is about the patient population, not the drug.
Weigh the youngest subgroup honestly
Children under 4 years showed favorable trends but did not reach significance on most measures, likely reflecting small sample size rather than true lack of benefit.
Account for the funding source
UCB funded the study and most authors report financial ties to the company, a common but relevant feature of industry-sponsored antiseizure medication research.
Consistent Across Subgroups, Not a Cannabis Finding: Eight Ways to Read This Analysis
This pooled analysis strengthens the case for fenfluramine across most Dravet syndrome patient subgroups, but it never tested cannabinoids. These eight perspectives keep that distinction clear while drawing out what is genuinely useful for clinicians managing CBD-treated patients.
What This Means If Your Child Has Dravet Syndrome and Uses CBD
This analysis found that fenfluramine reduced seizures and improved overall functioning in most children and teens with Dravet syndrome, regardless of age, how many other medications had already been tried, or their specific genetic variant, with the exception of the youngest children, where the sample was too small to draw firm conclusions.
It does not tell you anything about how fenfluramine works alongside CBD or Epidiolex, since cannabis-derived products were not part of this study. If your child is on a CBD-based regimen and you are considering fenfluramine, this analysis offers useful background on who tends to benefit, but the combination question still needs a direct conversation with your child’s treating clinician.
Useful Subgroup Guidance for an Increasingly Common Add-On
This pooled analysis gives clinicians something individual trials could not: reasonably powered subgroup data showing that fenfluramine’s benefit is not concentrated in one favorable population, but extends across age groups, treatment-resistant patients, and both SCN1A genotypes, with the youngest children as a clear exception requiring more cautious counseling.
Because international consensus now supports fenfluramine as an early add-on for Dravet syndrome, and because many patients in cannabis-focused and general neurology practices already use CBD-based regimens, this subgroup data is directly usable for sequencing and shared decision-making conversations, even though it was not designed to address combination therapy with cannabinoids.
A Non-Cannabinoid Study That Still Matters to Cannabis-Treated Patients
Dravet syndrome is the flagship indication for cannabidiol in American medicine, the condition that helped establish Epidiolex as the first FDA-approved cannabis-derived pharmaceutical, and cannabis medicine clinicians disproportionately see these patients as part of multidrug seizure-control regimens.
This trial contributes nothing about cannabinoids directly, but it strengthens the evidence base for a medication, fenfluramine, that these same patients are increasingly likely to be prescribed alongside CBD. Understanding which subgroups respond best to fenfluramine helps cannabis clinicians participate more knowledgeably in shared, multidisciplinary seizure-control planning.
Real Pooled Power, but Every Comparison Is Post Hoc
Pooling 348 patients across three RCTs gives this analysis meaningfully more statistical power than any single trial to detect subgroup-level effects, and most stratified comparisons reached conventional significance thresholds (p<0.05 or better) despite being subdivided into smaller groups.
Because none of these stratified comparisons were prespecified in the original trial protocols, the authors correctly label every p-value nominal rather than confirmatory, meaning the findings should be read as strong hypothesis-supporting evidence, not as definitively adjudicated statistical proof for each individual subgroup.
Genotype-Negative Patients Respond Too, a Practically Important Finding
One of this analysis’s more clinically useful findings is that fenfluramine’s efficacy did not depend on SCN1A-positive status; SCN1A-negative patients, roughly 10 to 15% of Dravet syndrome cases, showed comparable or even numerically greater seizure reduction than SCN1A-positive patients across most measures.
This matters because genetic testing results can take time, and some patients with clinically diagnosed Dravet syndrome never test positive for a pathogenic SCN1A variant. This analysis supports offering fenfluramine on clinical grounds without waiting for or requiring positive genetic confirmation.
Industry Funding, Nominal P-Values, and a Small Youngest Subgroup
UCB, fenfluramine’s manufacturer, funded this study, and the large majority of authors disclose research funding, consulting fees, or direct employment with the company. That does not make the findings false, but it is a real source of potential bias that deserves explicit mention rather than being buried in a conflict-of-interest footnote.
The youngest and smallest subgroup, patients under 4 years old, did not reach statistical significance on most measures, and a higher proportion of placebo-treated children in that age group showed improvement than older placebo-treated children, a pattern that complicates any confident claim about fenfluramine’s benefit in the youngest patients specifically.
A Template for Rare-Disease Subgroup Analysis, With Clear Next Steps
Pooling individual patient-level data across three separately conducted RCTs is a methodologically sound way to gain subgroup power in a rare disease where no single trial could recruit enough patients to answer these questions on its own, and the consistent endpoint definitions across all three trials strengthen the pooled comparison.
The clear next step the authors themselves identify is a prospectively designed study, or at minimum a preregistered subgroup analysis, that could confirm these post hoc findings, particularly for the youngest age group and for direct comparison against other add-on therapies including CBD-based regimens that many Dravet patients already use.
More Evidence-Based Options for a Rare, High-Burden Disease
Dravet syndrome carries a disproportionately high burden of seizures, developmental impairment, and premature mortality relative to its rarity, and subgroup-level evidence like this helps ensure that treatment-resistant patients, who have already failed multiple medications, are not overlooked when new therapies are being considered.
The relevant public health framing is precision: this analysis should be communicated as evidence for fenfluramine specifically, not folded into general claims about cannabinoid-based epilepsy treatment, since conflating the two would misrepresent both this fenfluramine data and the separate, real evidence base for CBD in the same disease.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this analysis test?
Researchers pooled patient-level data from three phase 3 randomized, double-blind, placebo-controlled trials of fenfluramine in 348 children and adolescents with Dravet syndrome, then stratified the results by age, number of previously attempted antiseizure medications, and SCN1A genotype to see whether fenfluramine’s benefit held up consistently across these subgroups.
Is this a study about cannabis or CBD?
No. Fenfluramine is a serotonergic medication unrelated to the endocannabinoid system, and no cannabis-derived product was tested in this study. Its relevance to cannabis medicine comes from the patient population, since CBD (Epidiolex) is the only FDA-approved cannabis-derived medicine for Dravet syndrome and many patients use both medications as part of a multidrug regimen.
Did fenfluramine reduce seizures?
Yes, in patients 4 years or older, fenfluramine reduced monthly convulsive seizure frequency by a median of 57.1% more than placebo (p<0.0001), with significant reductions across all three prior-medication strata and both SCN1A-positive and SCN1A-negative genotypes.
Did fenfluramine work as well in the youngest children?
Not with statistical certainty. In children younger than 4 years, the smallest subgroup, seizure reduction trended favorably (-42.1%) but did not reach statistical significance (p=0.0562), likely reflecting the small sample size in that age group rather than a confirmed lack of benefit.
Did genotype matter?
Fenfluramine was effective in both SCN1A-positive and SCN1A-negative patients, with SCN1A-negative patients showing numerically greater seizure reduction (-63.5% vs -53.8% for SCN1A-positive), though SCN1A-negative Dravet syndrome is uncommon, representing roughly 10-15% of cases.
What were the most common side effects?
Decreased appetite, diarrhea, and pyrexia were the most common treatment-emergent adverse events. Most began within about a month of starting treatment and resolved by the end of the study period in 82.6% of fenfluramine-treated patients.
Were there any serious safety concerns?
No cases of valvular heart disease or pulmonary arterial hypertension, the historical concerns with fenfluramine at much higher weight-loss doses, occurred in any of the three RCTs. The authors note that rare post-marketing cases have been reported in clinical use, supporting continued cardiac monitoring.
Who funded this study?
UCB, the manufacturer of fenfluramine (marketed as Fintepla), funded the analysis, and the large majority of the study’s authors report research funding, consulting fees, or employment relationships with the company.
What are the main limitations?
Every stratified subgroup comparison was post hoc and not prespecified in the original trials, so the authors label all p-values nominal rather than confirmatory. Treatment duration was short (14-15 weeks), several subgroups had small sample sizes, and the study did not include patients older than 18.
Does this study tell me how fenfluramine interacts with CBD?
No. This analysis did not test fenfluramine in combination with CBD or any cannabinoid, and no interaction or comparative efficacy data between the two is available from this study. That question requires direct discussion with a treating clinician familiar with both medications.
